Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.
Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.
复制标题
克隆造血突变与临床结局的关联：系统评价和荟萃分析。
DOI：
10.1002/ajh.26465
复制
发表时间：
2022-04
影响因子：
12.8
通讯作者：
Nead, Kevin T.
中科院分区：
文献类型：
--
作者：
Nowakowska, Malgorzata K.;Kim, Taebeom;Thompson, Mikayla T.;Bolton, Kelly L.;Deswal, Anita;Lin, Steven H.;Scheet, Paul;Wehner, Mackenzie R.;Nead, Kevin T.
克隆性造血（CH）突变在没有已知血液病的个体中很常见。在许多不同的研究中，CH突变与许多不良临床结局相关。我们系统地回顾了现有文献中与无血液病患者CH突变相关的临床结局。我们在PubMed、EMBASE和Scopus中检索了符合条件的研究。三名研究人员独立提取数据，每项研究都由第二作者进行验证。使用纽卡斯尔-渥太华量表评估偏倚风险。我们确定了32项研究，56个队列，研究CH突变和临床结局之间的关联。我们进行了Meta分析，比较了具有和不具有可检测CH突变的个体之间的结果。我们对心血管疾病进行了Meta分析（9项研究; HR = 1.61，95% CI = 1.26-2.07，p = .0002），血液系统恶性肿瘤（7项研究; HR = 5.59，95% CI = 3.31-9.45，p <0.0001），治疗相关骨髓肿瘤（4项研究; HR = 7.55，95%CI = 4.3-13.57，p < .001）和死亡（9项研究; HR = 1.34，95%CI = 1.2-1.5，p < .0001）。心血管疾病分析进一步按变异等位基因分数（VAF）和基因分层，仅与VAF ≥ 10%存在统计学显着相关性（HR = 1.42，95% CI = 1.24-1.62，p < .0001），以及每个基因的统计学显著性相关性与JAK 2中CH突变的最大效应幅度有关（HR = 3.5，95%CI = 1.84-6.68，p < .0001）。CH突变与血液系统恶性肿瘤相关性的分析表明，随着VAF阈值的增加，风险在数值上逐步增加。该分析强烈支持CH突变与无血液病个体中不良临床结局风险增加的临床意义相关，特别是与VAF阈值增加相关。
Clonal hematopoiesis (CH) mutations are common among individuals without known hematologic disease. CH mutations have been associated with numerous adverse clinical outcomes across many different studies. We systematically reviewed the available literature for clinical outcomes associated with CH mutations in patients without hematologic disease. We searched PubMed, EMBASE, and Scopus for eligible studies. Three investigators independently extracted the data, and each study was verified by a second author. Risk of bias was assessed using the Newcastle‐Ottawa Scale. We identified 32 studies with 56 cohorts that examine the association between CH mutations and clinical outcomes. We conducted meta‐analyses comparing outcomes among individuals with and without detectable CH mutations. We conducted meta‐analyses for cardiovascular diseases (nine studies; HR = 1.61, 95% CI = 1.26–2.07, p = .0002), hematologic malignancies (seven studies; HR = 5.59, 95% CI = 3.31–9.45, p < .0001), therapy‐related myeloid neoplasms (four studies; HR = 7.55, 95% CI = 4.3–13.57, p < .001), and death (nine studies; HR = 1.34, 95% CI = 1.2–1.5, p < .0001). The cardiovascular disease analysis was further stratified by variant allele fraction (VAF) and gene, which showed a statistically significant association only with a VAF of ≥ 10% (HR = 1.42, 95% CI = 1.24–1.62, p < .0001), as well as statistically significant associations for each gene examined with the largest magnitude of effect found for CH mutations in JAK2 (HR = 3.5, 95% CI = 1.84–6.68, p < .0001). Analysis of the association of CH mutations with hematologic malignancy demonstrated a numeric stepwise increase in risk with increasing VAF thresholds. This analysis strongly supports the association of CH mutations with a clinically meaningful increased risk of adverse clinical outcomes among individuals without hematologic disease, particularly with increasing VAF thresholds.
登录
查看更多内容
影响因子：
24
作者：
Libby P
通讯作者：
Libby P
DOI：
10.1056/nejmoa1409405
发表时间：
2014-12-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Genovese G;Kähler AK;Handsaker RE;Lindberg J;Rose SA;Bakhoum SF;Chambert K;Mick E;Neale BM;Fromer M;Purcell SM;Svantesson O;Landén M;Höglund M;Lehmann S;Gabriel SB;Moran JL;Lander ES;Sullivan PF;Sklar P;Grönberg H;Hultman CM;McCarroll SA
通讯作者：
McCarroll SA
在健康个体中预测急性髓样白血病的风险。
影响因子：
64.8
作者：
Abelson S;Collord G;Ng SWK;Weissbrod O;Mendelson Cohen N;Niemeyer E;Barda N;Zuzarte PC;Heisler L;Sundaravadanam Y;Luben R;Hayat S;Wang TT;Zhao Z;Cirlan I;Pugh TJ;Soave D;Ng K;Latimer C;Hardy C;Raine K;Jones D;Hoult D;Britten A;McPherson JD;Johansson M;Mbabaali F;Eagles J;Miller JK;Pasternack D;Timms L;Krzyzanowski P;Awadalla P;Costa R;Segal E;Bratman SV;Beer P;Behjati S;Martincorena I;Wang JCY;Bowles KM;Quirós JR;Karakatsani A;La Vecchia C;Trichopoulou A;Salamanca-Fernández E;Huerta JM;Barricarte A;Travis RC;Tumino R;Masala G;Boeing H;Panico S;Kaaks R;Krämer A;Sieri S;Riboli E;Vineis P;Foll M;McKay J;Polidoro S;Sala N;Khaw KT;Vermeulen R;Campbell PJ;Papaemmanuil E;Minden MD;Tanay A;Balicer RD;Wareham NJ;Gerstung M;Dick JE;Brennan P;Vassiliou GS;Shlush LI
通讯作者：
Shlush LI
DOI：
10.1016/s1470-2045(16)30627-1
发表时间：
2017-01
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Gillis NK;Ball M;Zhang Q;Ma Z;Zhao Y;Yoder SJ;Balasis ME;Mesa TE;Sallman DA;Lancet JE;Komrokji RS;List AF;McLeod HL;Alsina M;Baz R;Shain KH;Rollison DE;Padron E
通讯作者：
Padron E
DOI：
10.1126/science.aan4673
发表时间：
2019-11-01
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Jaiswal S;Ebert BL
通讯作者：
Ebert BL